Immunomedics' 131I-Labetuzumab found safe in colorectal cancer patients

By Elaine Rigoli

Tampa, Fla., June 2 - Immunomedics, Inc. reported Friday that repeated use of its radiolabeled antibody against the carcinoembryonic antigen (CEA) 131I-labetuzumab has been found to be safe and well-tolerated by patients with colorectal cancer that has metastasized to the liver.

Twelve patients have been enrolled, and within two months of surgery to remove liver metastases of colorectal cancer, patients received a first dose of 50 mCi/m2 of 131I-labetuzumab, according to a news release.

Three months after the first radioimmunotherapy, a second infusion of the radiolabeled, humanized, CEA-antibody was given in the same amount.

Transient grade-4 myelosuppression occurred in four out of 12 patients after the first dose, but no cumulative toxicity was seen thus far in seven patients who received the second infusion, the release said.

Complete bone marrow recovery was reported in all cases.

At a median follow-up of four months, no cancer recurrence has been detected in the 12 patients enrolled to date. In all, a total of 15 patients will be enrolled in this study.

Immunomedics is a Morris Plains, N.J.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.